01—Abstract
Summary
Summary of the 8-K filed October 7, 2026. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific (BSX) filed an 8-K on October 7, 2026 disclosing two leadership changes and a structural reorganization.
Joe Fitzgerald, currently EVP and Group President, Cardiovascular, will become EVP and Chief Operating Officer effective January 1, 2027, overseeing global operations, business units, and regions. His offer letter provides a $1,050,000a base salary, a 110% bonus target, and a 2027 equity award with a total grant-date fair value of $7,000,000, vesting 25% per year. Concurrently, the company will establish three reportable segments effective January 1, 2027: Interventional Therapies, Rhythm Solutions, and MedSurg.
The company says the structure is designed to speed decision-making and support strategic capital allocation. On the finance side, Emily Woodworth (Collins) will step down as Chief Accounting Officer effective March 1, 2027, remaining in a finance transformation role. Mark Bickel, currently SVP, Finance and Global Controller of Cardiovascular, will succeed her as CAO on the same date.
The filing states Woodworth's transition is not due to any disagreement on financial statements, internal controls, operations, policies, or practices, which is a standard but important disclosure for investors to note. For investors, the most significant items are the segment realignment, which will change how BSX reports results and may affect comparability with prior periods, and the continuity of senior operating leadership under Fitzgerald.
The filing references the anticipated Penumbra acquisition as part of the Interventional Therapies segment, so its closing timing will also matter. Segment-level financial details and any reporting-change recasts are not included in this filing and should be reviewed in forthcoming disclosures.
02—Key points
Key Highlights
- Joe Fitzgerald promoted to EVP and Chief Operating Officer effective January 1, 2027, overseeing global operations, business units, and regions
- Compensation for Fitzgerald includes a $1.05M base salary, 110% bonus target, and a 2027 equity award with a $7.0M grant-date fair value
- Three new reportable segments effective January 1, 2027: Interventional Therapies, Rhythm Solutions, and MedSurg, which may affect comparability of segment reporting
- Lance Bates will lead Interventional Therapies (including the pending Penumbra business), Nick Spadea-Anello will lead Rhythm Solutions, and Stephen Morse will lead MedSurg and Asia Pacific, all reporting to Fitzgerald
- Emily Woodworth (Collins) steps down as Chief Accounting Officer effective March 1, 2027, moving to SVP, Global Finance Controller and Finance Transformation; the company states no disagreement was involved
- Mark Bickel, currently SVP, Finance and Global Controller of Cardiovascular, named Chief Accounting Officer effective March 1, 2027
- Management frames the reorganization as enabling faster decisions, greater capacity for long-term growth priorities, and strategic allocation of investments across the portfolio
03—Questions
Frequently Asked Questions
What is changing in Boston Scientific's operating structure?
Effective January 1, 2027, BSX will organize its business into three reportable segments: Interventional Therapies (Interventional Cardiology, Vascular Therapies, and Interventional Oncology & Embolization), Rhythm Solutions (Electrophysiology, WATCHMAN, and Cardiac Rhythm Management & Diagnostics), and MedSurg (Endoscopy, Urology, and Neuromodulation). All three segment leaders will report to the new COO, Joe Fitzgerald.
What compensation is Joe Fitzgerald receiving in his new role?
His offer letter provides a $1,050,000 annual base salary, an annual bonus target of 110% of base salary, eligibility to defer up to 75% of his bonus, and a 2027 annual equity award with a total grant-date fair value of $7,000,000, split between non-qualified stock options and RSUs (including performance-based RSUs) that vest 25% per year. He also keeps Executive Retirement Plan and Change in Control Agreement eligibility.
Why is Emily Woodworth stepping down as Chief Accounting Officer?
The filing says her transition is not due to any disagreement with the company on financial statements, internal control over financial reporting, operations, policies, or practices. She will remain with the company as SVP, Global Finance Controller and Finance Transformation, and Mark Bickel succeeds her as CAO on March 1, 2027.
How might the segment change affect investors analyzing BSX results?
The new segment structure will likely change how revenue and operating performance are reported, so prior-period figures may need to be recast for comparability. The filing does not provide recast financials, so investors should watch for revised segment disclosures in upcoming earnings releases and SEC filings. The Penumbra acquisition, once closed, will be included in the Interventional Therapies segment.
04—Continue